Stockscreener 앱 받기
11.45
10.36%
-1.29
전일 마감가:
$12.74
열려 있는:
$11.85
하루 거래량:
497.35K
Relative Volume:
0.73
시가총액:
$820.86M
수익:
$133.62M
순이익/손실:
$-177.37M
주가수익비율:
-3.9619
EPS:
-2.89
순현금흐름:
$23.50M
1주 성능:
-15.72%
1개월 성능:
+5.55%
6개월 성능:
+33.57%
1년 성능:
-17.84%
1일 변동 폭
$10.89
$11.98
1주일 범위
$10.89
$13.57
52주 변동 폭
$6.92
$18.69
Xencor Inc Stock (XNCR) Company Profile
명칭
Xencor Inc
전화
626-305-5900
주소
465 N. HALSTEAD ST., PASADENA, CA
Compare XNCR vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
XNCR
Xencor Inc
|
11.49 | 909.77M | 133.62M | -177.37M | 23.50M | -2.89 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.13 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
769.14 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
728.00 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
323.39 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
294.78 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Xencor Inc Stock (XNCR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-11-24 | 개시 | Truist | Buy |
| 2025-10-29 | 업그레이드 | Barclays | Underweight → Overweight |
| 2025-09-17 | 재개 | Barclays | Underweight |
| 2025-09-03 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2025-04-21 | 개시 | William Blair | Outperform |
| 2024-12-12 | 개시 | Wells Fargo | Overweight |
| 2024-12-02 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2024-04-16 | 재확인 | BTIG Research | Buy |
| 2024-02-28 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2023-05-19 | 개시 | BofA Securities | Buy |
| 2022-12-06 | 개시 | Cowen | Outperform |
| 2022-10-13 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2022-09-21 | 개시 | JP Morgan | Overweight |
| 2022-07-06 | 재개 | Canaccord Genuity | Buy |
| 2022-02-11 | 개시 | BMO Capital Markets | Outperform |
| 2022-01-21 | 개시 | SMBC Nikko | Outperform |
| 2021-12-15 | 개시 | H.C. Wainwright | Buy |
| 2021-10-15 | 재개 | BTIG Research | Buy |
| 2021-02-24 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2020-03-04 | 개시 | Barclays | Underweight |
| 2020-02-25 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2020-01-30 | 개시 | RBC Capital Mkts | Outperform |
| 2019-11-20 | 재개 | Guggenheim | Neutral |
| 2019-08-07 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2019-08-07 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2019-06-13 | 개시 | Mizuho | Buy |
| 2019-04-12 | 개시 | Guggenheim | Buy |
| 2019-03-27 | 개시 | Berenberg | Buy |
| 2019-03-15 | 개시 | Raymond James | Outperform |
| 2018-09-10 | 재개 | BTIG Research | Buy |
| 2018-03-28 | 재개 | Leerink Partners | Outperform |
| 2017-03-02 | 개시 | Instinet | Neutral |
| 2017-03-02 | 재확인 | Wedbush | Outperform |
| 2016-10-04 | 개시 | Piper Jaffray | Overweight |
| 2015-12-22 | 개시 | Canaccord Genuity | Buy |
| 2015-08-05 | 재확인 | MLV & Co | Buy |
| 2015-02-12 | 재확인 | Oppenheimer | Outperform |
| 2015-01-28 | 재확인 | MLV & Co | Buy |
| 2014-07-11 | 개시 | Oppenheimer | Outperform |
모두보기
Xencor Inc 주식(XNCR)의 최신 뉴스
Xencor (NASDAQ:XNCR) VP Sells $31,689.70 in Stock - MarketBeat
Insider Selling: Xencor (NASDAQ:XNCR) SVP Sells 1,492 Shares of Stock - MarketBeat
Xencor SVP Eckert sells $17,747 in shares - Investing.com Nigeria
Xencor sr. VP Desjarlais sells $31,676 in stock - Investing.com
Dahiyat, Xencor CEO, sells $80k in XNCR stock - Investing.com
Xencor: Buy Rating Reaffirmed on Pipeline Momentum Despite Ultomiris Royalty Headwind - TipRanks
Xencor faces royalty dispute with Alexion over Ultomiris sales - Investing.com
Xencor Updates Outlook Amid Ultomiris Royalty Dispute - TipRanks
Xencor says Alexion disputes U.S. Ultomiris royalties; updates cash guidance to $380–400M - TradingView
Xencor faces $100M hit as Ultomiris US royalty checks stop - Stock Titan
XNCR Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
(XNCR.O) | Stock Price & Latest News - Reuters
[144] Xencor Inc SEC Filing - Stock Titan
John Desjarlais plans to sell 2,663 XNCR shares (XNCR) — Form 144 notice - Stock Titan
Xencor at TD Cowen Conference: Strategic Focus on Oncology and Autoimmune By Investing.com - Investing.com South Africa
Xencor at TD Cowen Conference: Strategic Focus on Oncology and Autoimmune - Investing.com
Update Recap: Should value investors consider Xencor IncEarnings Recap Report & High Yield Equity Trading Tips - baoquankhu1.vn
Xencor, Inc. Experiences Revision in Stock Evaluation Amid Market Dynamics - Markets Mojo
Responsive Playbooks and the XNCR Inflection - Stock Traders Daily
XNCR PE Ratio & Valuation, Is XNCR Overvalued - Intellectia AI
Xencor (NASDAQ:XNCR) Stock Rating Lowered by Wall Street Zen - MarketBeat
Xencor, Inc. (XNCR) Investor Outlook: Unpacking the 113% Potential Upside in Biotech Innovation - DirectorsTalk Interviews
Xencor, Inc. $XNCR Shares Purchased by Primecap Management Co. CA - MarketBeat
Analysts Offer Insights on Healthcare Companies: Agilent (A), Xencor (XNCR) and Pennant Group (PNTG) - The Globe and Mail
Barclays Raises Xencor (XNCR) Price Target to $27, Maintains Ove - GuruFocus
Xencor (NASDAQ:XNCR) Shares Up 10.4% After Better-Than-Expected Earnings - MarketBeat
Xencor (NASDAQ:XNCR) Given New $27.00 Price Target at Barclays - MarketBeat
Xencor Inc earnings beat by $0.51, revenue fell short of estimates - Investing.com Nigeria
Xencor (XNCR) Losses Narrow On Trailing Basis Challenging Persistent Bearish Narratives - Sahm
Xencor (XNCR) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance
Xencor Inc reports results for the quarter ended September 30Earnings Summary - TradingView
Xencor files for mixed shelf - marketscreener.com
Xencor (NASDAQ:XNCR) Issues Earnings Results - MarketBeat
Earnings Flash (XNCR) Xencor, Inc. Reports Q4 Revenue $28.2M, vs. FactSet Est of $30.0M - marketscreener.com
Xencor: Q4 Earnings Snapshot - marketscreener.com
Xencor Q4 revenue misses expectations, net loss narrows - TradingView
Xencor Reports Fourth Quarter and Full Year 2025 Financial Results - Bluefield Daily Telegraph
Xencor (XNCR) trims 2025 loss and outlines major trial plans - Stock Titan
Xencor recently updated its financial forecast, announcing that by the end of 2026, the company's cash reserves are expected to reach between $400 million and $430 million. - Bitget
Aug Catalysts: Is Xencor Inc a top pick in the sectorJuly 2025 Chart Watch & Real-Time Stock Movement Alerts - baoquankhu1.vn
Aug Fed Impact: What hedge funds are buying Xencor Inc2025 Pullback Review & Weekly Watchlist of Top Performers - baoquankhu1.vn
Xencor to Participate at Upcoming Investor Conferences - Business Wire
Xencor Inc expected to post a loss of 60 cents a shareEarnings Preview - TradingView
Xencor, Inc. (XNCR) Stock Analysis: Exploring A Biotech Giant With 145% Upside Potential - DirectorsTalk Interviews
What hedge funds are buying Xencor Inc.July 2025 Setups & Free High Return Stock Watch Alerts - mfd.ru
Will Xencor Inc. stock hit new highs in YEAREarnings Overview Report & Stepwise Swing Trade Plans - mfd.ru
Earnings Beat: Is Xencor Inc stock showing strong momentumDollar Strength & High Accuracy Swing Entry Alerts - baoquankhu1.vn
Xencor (XNCR) to Release Quarterly Earnings on Thursday - MarketBeat
Big Money Moves: What is the Moat Score of Xencor Inc2025 Momentum Check & Long-Term Growth Portfolio Plans - baoquankhu1.vn
Aug Swings: Can TACOU be recession proofTake Profit & Safe Capital Growth Stock Tips - baoquankhu1.vn
CTLA-4 Inhibitors Competitive Landscape Research Report 2026: Comprehensive Insights About 40+ Companies and 50+ Drugs by Product Type, Stage, Route of Administration, and Molecule Type - GlobeNewswire Inc.
Xencor Inc (XNCR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Xencor Inc 주식 (XNCR) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Eckert Celia | SVP, GENERAL COUNSEL |
Mar 03 '26 |
Sale |
11.90 |
1,492 |
17,747 |
81,929 |
| Dahiyat Bassil I | PRESIDENT & CEO |
Mar 03 '26 |
Sale |
11.90 |
6,758 |
80,387 |
567,792 |
0.50%
자본화:
|
볼륨(24시간):